-
Nurix Therapeutics NASDAQ:NRIX Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
Location: | Website: www.nurixtx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
990.9M
Cash
448.1M
Avg Qtr Burn
-24.29M
Short % of Float
18.78%
Insider Ownership
1.45%
Institutional Own.
97.75%
Qtr Updated
08/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NX-5948 Details Cancer, B-cell malignancies | Phase 1 Data readout | |
NX-5948 Details Waldenstrom macroglobulinemia | Phase 1 Data readout | |
NX-2127 Details Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma | Phase 1 Data readout | |
NX-1607 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
NX-1607 + paclitaxel Details Solid tumor/s, Cancer | Phase 1a Data readout | |
DeTIL-0255 Details Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer | Failed Discontinued |